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BACKGROUND. The combination of external-beam radiotherapy and brachyther-
apy is used commonly to treat men with prostate cancer. In this analysis, the
authors examined the rate of biochemical recurrence (BR) and late grade 3 gen-
itourinary (GU) and gastrointestinal (GI) toxicity after treatment with external-
beam radiotherapy and brachytherapy in a multiinstitutional, cooperative group
setting.
METHODS. All eligible patients received external-beam radiotherapy (45 Gray [Gy]
in 25 fractions) followed 2 to 6 weeks later by an interstitial implant using io-
dine-125 to deliver an additional 108 Gy. BR was defined in 2 ways: according to
the American Society for Therapeutic Radiology and Oncology (ASTRO) Consen-
sus Definition (ACD) and according to the Phoenix definition (PD) (prostate-spe-
cific antigen nadir þ2 ng/mL). The Radiation Therapy Oncology Group(RTOG)/
European Organization for Research and Treatment of Cancer late radiation mor-
bidity scoring system was used to grade all toxicity.
RESULTS. One hundred thirty-eight patients were enrolled, and 130 were eligible
for the current analysis. The median follow-up for surviving patients was 49
months (range, 20–60 months). The 48-month estimate of late grade 3 GU/GI
toxicity was 15% (95% confidence interval [95% CI], 8–21%), and the 48-month
estimate of BR was 19% (95% CI, 12–26%) and 14% (95% CI, 8–20%) according to
the ACD and PD, respectively.
CONCLUSIONS. The morbidity observed in this multiinstitutional, cooperative
group study was slightly higher than that reported in recent RTOG studies using
brachytherapy alone or high-dose external-beam radiotherapy. The BR rate
observed in this report was similar to that observed with high-dose external-
beam radiotherapy alone in similar patients. Cancer 2007;109:1506–12.
 2007 American Cancer Society.
KEYWORDS: I-125, biochemical recurrence, external-beam radiotherapy, gastroin-
testinal toxicity, genitourinary toxicity, permanent-source brachytherapy.
T he utilization of brachytherapy in the treatment of men withclinically localized prostate cancer has increased dramatically in
the past 15 years.1,2 According to the 1999 Patterns of Care Study,
>33% of men with prostate cancer who were treated with radiother-
apy received brachytherapy as a component of their treatment.1 The
results from that study also indicated that approximately 50%
of men who were treated with brachytherapy received supplemental
external-beam radiotherapy. Results from a recent study by the
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of men with prostate cancer indicated that the use
of supplemental external-beam radiotherapy has in-
creased over the past decade.3
Historically, the combining of external-beam
radiotherapy with brachytherapy offered several
potential advantages compared with the use of either
treatment alone: 1) greater intraprostatic dose than
can be achieved with either modality alone, 2) the
ability to deliver doses to the periprostatic region
that cannot be achieved with brachytherapy alone,
and 3) the ability to fill-in low-dose regions that may
result from inaccurate source placement. At the
same time, combination therapy may increase the
risk of normal tissue injury compared with either
modality alone. For a true improvement in the thera-
peutic ratio, an increased probability of tumor con-
trol should not be overshadowed by an increase in
normal tissue complications.
A number of reports describing the efficacy and
morbidity of brachytherapy combined with supple-
mental external-beam radiotherapy have been pub-
lished.4–9 The majority of those reports represented
retrospective, single-institution experiences, and it is
not known whether those results can be generalized to
the broader community. Some reports have suggested
that the morbidity associated with a combination of
external-beam radiotherapy and brachytherapy was
not dramatically different than that observed with
brachytherapy alone,10–12 whereas others observed
more morbidity after combined brachytherapy and
external-beam radiotherapy.13–15
It was in this context that the Radiation Therapy
Oncology Group (RTOG) designed the current Phase
II trial. The objective of the trial was estimate the
rate of gastrointestinal (GI) and genitourinary (GU)
morbidity after patients received a combination of
external-beam radiotherapy and permanent-source,
interstitial brachytherapy with iodine-125 (I-125). A
preliminary report that examined acute and late tox-
icity has been published.16 This report represents an
update on the morbidity observed in the study
cohort. In addition, the estimated rates of biochem-
ical recurrence (BR) in this population are reported
for the first time.
MATERIALS AND METHODS
Participants
Eligible patients had histologically confirmed adeno-
carcinoma of the prostate gland, and they were
required to have clinical stage T1 to T2b. Serum pros-
tate-specific antigen (PSA) levels and a Gleason score
were required prior to treatment in all patients. If the
Gleason score was <7, then the PSA was required to
be >10 ng/mL and 20 ng/mL. If the Gleason score
was 7, then the PSA was required to be 20 ng/mL.
Patients with clinical evidence of extracapsular exten-
sion (T3), a pretreatment PSA level >20 ng/mL, or a
Gleason score >7 were not eligible.
Additional eligibility criteria required that the
prostate volume be 60 cc on transrectal ultrasound
(TRUS) prior to external-beam radiotherapy, and
only men with an International Prostate Symptom
Score 18 were eligible. A Zubrod performance status
of 0 or 1 was required. No previous pelvic radiation,
radical prostate surgery, or chemotherapy was allowed.
Short-term androgen deprivation 6 months was
allowed. A history of prior transurethral resection of
prostate (TURP) or hip prosthesis made a patient ineli-
gible. All patients completed an informed consent
document prior to entering the trial. All institutions
that participated were required to have the protocol
reviewed by an Institutional Review Board (or equiva-
lent) in accordance with the precepts of the Helsinki
declaration. The study was activated in November 2000
and, having met accrual goals, was closed in November
2001.
Patients received a combination of external-
beam radiotherapy and interstitial brachytherapy
using I-125. The specifics of treatment and quality
assurance methods have been described previously.16
Briefly, patients received a combination of external-
beam radiotherapy and interstitial brachytherapy
using I-125. External-beam radiotherapy was deliv-
ered with megavoltage (MV) photon beams (>6 MV)
to the prostate and seminal vesicles (CTV). A CTV-
to-block margin from 1.5 cm to 2.0 cm was required.
The prescribed dose was 45 Gray (Gy) in 25 fractions
(1.8 Gy per fraction). The prescribed dose was
defined on the central axis at the intersection of the
beams. The permitted dose variation was 5%.
Brachytherapy was completed from 2 to 6 weeks
after external-beam radiotherapy. Preplanning meth-
ods were required. For treatment-planning purposes,
the TRUS volume was considered the CTV. The CTV
was enlarged in the anterior, lateral, inferior, and
superior dimensions to create a planning target volume
(PTV). The CTV was not expanded posteriorly toward
the rectum. The prescription dose was 108 Gy and was
to be delivered to the PTV. The recommended activity
per source was 0.30 to 0.51 U (0.25–0.4 mCi).
Follow-up Studies and Toxicity Evaluation
Patients were evaluated weekly during external-beam
radiotherapy for acute toxicity. Follow-up visits were
completed 1 month, 3 months, 6 months, 9 months,
and 12 months after implantation; every 6 months
for the next 2 years; and annually thereafter. History,
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physical examination (including digital rectal exami-
nation), serum PSA measurement, and toxicity eva-
luation were performed at each follow-up visit. The
RTOG/European Organization for Research and
Treatment of Cancer Late Morbidity scale was used
to grade all late toxicity. The lead author personally
reviewed all cases that reported grade 3 toxicity.
Study Endpoints and Statistical Analysis
The primary objective of this study was to estimate the
rate of acute and late Grade 3 GU and GI toxicity af-
ter treatment with external-beam radiotherapy and
permanent-source brachytherapy. Secondary end-
points included an estimation of the rates of freedom
from BR, disease-specific survival, and overall survival.
For the current report, we examined late grade 3 GU
and GI morbidity and a secondary endpoint, BR.
For the purposes of the current analysis, acute
toxicity was defined as toxicity that occurred within
9 months of the beginning of radiotherapy, and late
toxicity was defined as toxicity that occurred >9
months after the start of radiotherapy. We believed
that this distinction was justified because of the time
course of radiation delivery after brachytherapy with
I-125. The study was designed to test whether the
rate of grade 3 GU or GI toxicity was >10% at 18
months after the beginning of radiotherapy. The
sample size was determined so that the probability
of rejecting the treatment because of excessive late
toxicity would be s 90% if the true toxicity rate was
20%. The time to the first occurrence of a late grade
3 GU/GI toxicity was estimated by using the cumu-
lative incidence method.
BR was defined in 2 ways; according to the
American Society for Therapeutic Radiology and On-
cology (ASTRO) Consensus definition (3 consecutive
rises with time of recurrence backdated to the mid-
point between the PSA nadir and the first PSA rise)17
and the Phoenix definition (PSA nadir þ2 ng/mL).18
Any PSA rise great enough to provoke the initiation
of salvage hormone therapy was considered BR
according to either definition. For each definition,
the BR rate was estimated by using the cumulative
incidence method.19 Overall survival was estimated
according to the Kaplan-Meier method.20
RESULTS
Patient Characteristics
One hundred thirty-eight men were entered on the
study between November 2000 and November 2001.
The outcome of 8 patients was not included in this
analysis. Six patients were considered ineligible (3
patients secondary to hormone therapy that violated
eligibility criteria, 1 patient had a pretreatment
American Urological Association score >18, 1 patient
had been treated prior to study entry, and 1 patient
had a PSA >20 ng/mL). Two additional patients were
not included in the analysis, because 1 patient with-
drew consent, and another did not receive any proto-
col therapy. Late toxicity data were available for all
130 men who were entered and eligible. All radio-
therapy data were available for 129 of 130 men, and
complete follow-up data were available for 127 of
130 men. This report includes all information
received, reviewed, and entered at the RTOG head-
quarters as of May 2006. Follow-up ranged from 12
months to 60 months (median, 49 months).
The pretreatment characteristics of all 130
patients who were entered and eligible are provided
in Table 1. The median age of this cohort was 67
years (range, 40–80 years). The vast majority of these
men had an excellent performance status, and 86%
of them were white. The median PSA for this group
was 7.6 ng/mL. Nearly 80% of men in this group had
cancers with a Gleason score of 7. Twenty-seven per-
TABLE 1
Pretreatment Characteristics of the Study Population (n = 130)













African American 10 8
Asian 3 2














PSA indicates prostate-specific antigen.
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cent of men received androgen-deprivation therapy
prior to and concurrent with radiotherapy. Greater
than 20 institutions contributed patients to this trial.
The median number of patients accrued per institu-
tion was 5 (range, 1–24 patients per institution). The
average monthly accrual was 11 cases per month,
and most patients were accrued in the last 6 months
that the study was open.
Late Toxicity
No patient experienced grade 5 late toxicity. Grade 4
GU toxicity (bladder necrosis) was reported in 2
patients. In each man, the necrosis occurred in the
region of the bladder neck. One man had bladder ne-
crosis that was preceded by a TURP. No grade 4 GI
toxicity has been observed. Of the 9 patients who
reportedly developed grade 3 late toxicity, 5 patients
had urinary toxicity (dysuria in 3 and hematuria in
2), and 4 patients had Grade 3 proctitis. The time to
late grade 3 toxicity was calculated as the number
of months subsequent to 9 months after the start of
RT until the event/censoring.
The 18-month month estimate of late grade 3
GU/GI toxicity is 8% (95% confidence interval [95%
CI], 3–12%). The null hypothesis that the 18-month
late grade 3 GU/GI toxicity is >10% was not rejected
at the .05 a level (Z-statistic ¼ 4.068; P ¼ .99). Given
the length of follow-up available, it is also appropriate
to report later toxicity. The 48-month estimate of late
grade 3 GU/GI toxicity is 15% (95% CI, 8–21%). The
cumulative incidence estimate of grade 3 GU/GI
toxicity is illustrated in Figure 1.
BR
Two definitions of BR were used in this analysis, as
described above. According to the ASTRO definition,
25 men developed a BR during the period of follow-
up. The 48-month estimate of BR using the ASTRO
definition is 19% (95% CI, 12–26%). The cumulative
incidence estimate of BR according to the ASTRO
definition is illustrated in Figure 2.
Using the Phoenix definition, a total of 17 BRs
were observed. The 48-month estimate of BR using
the Phoenix definition is 14% (95% CI, 8–20%). The
cumulative incidence estimate of BR according to
the Phoenix definition is illustrated in Figure 3.
Overall Survival and Clinical Recurrence
Twelve men have died during the period of follow-
up. There have been no prostate cancer-related
deaths reported. The 48-month Kaplan–Meier esti-
mate of overall survival in this cohort is 91% (95%
CI, 86–97%). Two clinical recurrences have been
documented: One patient developed local recur-
rence/persistence at 16 months, and another patient
FIGURE 1. Time to late grade 3 genitourinary/gastrointestinal toxicity.
RT indicates radiotherapy. FIGURE 2. Time to biochemical recurrence (American Society for Thera-
peutic Radiology and Oncology definition).
FIGURE 3. Time to biochemical recurrence (Phoenix definition).
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developed evidence of distant metastatic disease at
42 months.
DISCUSSION
The primary objective of this study is to estimate the
rate of acute and late grade 3 GU/GI toxicity after
treatment with external-beam radiotherapy and per-
manent-source brachytherapy. The current analysis
indicates that the cumulative incidence of grade 3
and 4 GU/GI toxicity is 15% 4 years after treatment.
No grade 5 toxicities have been reported. The most
severe toxicity observed has been bladder necrosis in
2 patients; no rectal necrosis or colostomies have
been reported. This 15% estimate is higher than a
preliminary estimate16 but is consistent with the
time course of radiation-induced GU/GI toxicity
observed after external-beam radiotherapy and
brachytherapy to pelvic tumors.21 How does this rate
of toxicity compare with other radiation treatment
methods studied within the RTOG framework?
Over the past 3 decades, the RTOG has collected
toxicity information on a large number of patients
who received external-beam radiotherapy alone. Two
recent studies provided information that is germane
to the results provided in this report. RTOG 94-06 is
a Phase I/II dose-escalation study that was designed
to determine the maximum tolerated dose that can
be delivered to the prostate gland using 3-dimen-
sional conformal radiotherapy. The observed toxici-
ties at all 5 dose levels in that study have been
reported.22–26 The most recent report provided an
estimate of grade 3 GU/GI toxicity for dose levels
III (79.2 Gy in 1.8-Gy fractions) and dose level V
(78 Gy in 2-Gy fractions).25 In that report from
Michalski et al, the estimated 24-month incidence of
grade 3 GU/GI toxicity ranged from 1% to 7% with
the higher rates observed at dose level V. This level
of toxicity is comparable to the 18-month estimate of
3.3% provided in the preliminary analysis of RTOG
0019.16 It remains to be determined whether the GU/
GI morbidity in RTOG 9406 will increase over the
next several years like what has been observed in
RTOG 0019.
A second dataset includes patients who were
treated on the randomized dose-escalation trial
reported by Zietman et al.27 That study (Proton
Radiation Oncology Group/RTOG 9509) included
nearly 400 men and randomly assigned them to a
control arm (total dose, 70.2 Gy) or an experimental
arm (total dose, 79.2 Gy). The final dose (19.8–28.8
Gy) was delivered by proton-beam therapy. At a me-
dian follow-up of 5.5 years, the incidence of BR was
lower in the experimental arm. Those authors did
not provide actuarial estimates, but the crude rate of
late grade 3 GU/GI toxicity reportedly was from 1%
to 2%. No late grade 4 or 5 toxicity was reported.
The RTOG also has collected information on late
GU/GI toxicity after permanent-source brachyther-
apy. In addition to the information provided in this
report, the RTOG has completed accrual to another
Phase II trial examining the use of permanent low-
dose-rate brachytherapy alone, RTOG 9805. That
study included men with favorable-risk prostate can-
cer, and all men were treated with prostate brachy-
therapy alone (I-125 at a prescription dose of 145
Gy). The preliminary analysis of that study has been
published.28 Ninety-four men were eligible for analy-
sis of late toxicity with a median follow-up of 5.3
years. Two patients developed late grade 3 GU toxic-
ity, and the cumulative incidence of grade 3 GU tox-
icity was <3% at 5 years. No late grade 3 GI toxicity
or grade 4 or 5 GU/GI toxicity was reported.
Table 2 summarizes the late grade 3 GU/GI
morbidity observed in several recent RTOG trials for
men with clinically localized prostate cancer.25–27 All
of those studies used similar reporting methods and
toxicity scales. The length of follow-up is approxi-
TABLE 2
Reported Late Grade ‡3 Genitourinary/Gastrointestinal Toxicity in Recent Radiation Therapy Oncology Group
Trials of Men With Clinically Localized Prostate Cancer
Study no. Radiotherapy dose No. of patients Median FU, mo
% Late grade 3
GU/GI toxicity
0019 45 Gy in 1.8-Gy fractions
and 108 Gy I–125
130 49 15 at 48 mo
9406 (Level III) 79.2 Gy in 1.8-Gy fractions 170 56–62 1–2 at 24 mo*
9406 (Level V) 78 Gy in 2-Gy fractions 218 29 5–7 at 24 mo*
9509 79.2 Gy in 1.8-Gy fractions 195 66 1–2*
9805 145 Gy I–125 94 64 <3 at 60 mo
FU indicates follow-up; GU/GI, genitourinary/gastrointestinal; Gy, grays; I–125, iodine-125.
* Represents a crude percentage: Actuarial figures are not provided.
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mately 5 years in all series except for the patients
treated at dose level V in RTOG 9406. Although com-
parisons across series should be undertaken with an
abundance of caution, it appears that the observed
late grade 3 GU/GI toxicity is higher in patients
treated on RTOG 0019 compared with the toxicity
observed in other studies, with the possible excep-
tion of dose level V on RTOG 9406.
The increased morbidity of brachytherapy and
supplemental external-beam radiotherapy compared
with brachytherapy alone has been observed by
others. Albert et al. examined the rate of late GU/GI
toxicity in men who were treated with magnetic reso-
nance image-guided prostate brachytherapy with or
without external-beam radiotherapy. After a median
follow-up of 2.8 years, the rate of rectal bleeding and
radiation cystitis was significantly greater in the
patients who had received supplemental external-
beam radiotherapy.13 Investigators at Duke University
observed a similar phenomenon when they exam-
ined rectal toxicity after prostate brachytherapy.
Those authors studied 134 men and observed that
the addition of external-beam radiotherapy was asso-
ciated with more rectal toxicity.14 In a recent report
from San Antonio, Sarosdy described toxicity in 177
men who received brachytherapy alone (n ¼ 100
patients) or brachytherapy and supplemental exter-
nal-beam radiotherapy (n ¼ 77 patients). In that
study, the rates of rectal bleeding and of fecal and
urinary diversion were higher in the men who
received both brachytherapy and supplemental exter-
nal-beam radiotherapy. It is important to point out
that increased morbidity of supplemental external-
beam radiotherapy has not been observed by all
investigators.10–12 It is interesting to speculate that
this lack of consistency may be attributable to subtle
differences in dose-volume relationships.
Compared with 3-dimensional conformal radio-
therapy, prostate brachytherapy is characterized by a
large degree of dose inhomogeneity. It is not unusual
to have regions within the prostate gland receiving
from 200% to 300% of the prescription dose,
although most brachytherapists attempt to minimize
these high-dose volumes.29 The dose-volume-toxicity
relationships after prostate brachytherapy are evol-
ving, and no consensus exists to date.30 Unfortu-
nately, the simple dosimetric evaluation in the
current report precludes any meaningful dose-vol-
ume analysis.
A secondary objective of the current study was
to determine the rate of BR after treatment with
external-beam radiotherapy and interstitial brachy-
therapy. Depending on the definition, either 14% or
19% of men had evidence of BR in the first 48
months after treatment. This result is similar to the
results reported in intermediate-risk patients who
were treated with high-dose external-beam radiother-
apy alone27,31 or with external-beam radiotherapy
and brachytherapy.4 The rate of BR was slightly lower
in the current report but, this is to be expected with
the slightly shorter follow-up.
The results from several recent randomized trials
provide evidence for a dose response in clinically loca-
lized prostate cancer.27,32,33 Brachytherapy combined
with external-beam radiotherapy has been used for
nearly 20 years in men with prostate cancer as a strat-
egy to increase the biologic dose. If the therapeutic ra-
tio is be enhanced, however, then normal tissue
toxicity should remain low. It is axiomatic that conclu-
sive statements on the toxicity or efficacy of a particu-
lar treatment require randomized controlled trials. The
results of the current study suggest that the combina-
tion of brachytherapy and external-beam radiotherapy
is associated with a rate of BR that is similar to that
achieved with other dose-escalation strategies (eg, 3-
dimensional conformal or intensity-modulated radio-
therapy) but may have an increased toxicity profile.
The RTOG currently is accruing men with intermedi-
ate-risk disease to a randomized trial comparing com-
bined external-beam radiotherapy plus brachytherapy
with brachytherapy alone (RTOG 0232; B. Prestidge,
Principal Investigator). That trial will determine the
value, if any, of external-beam radiotherapy added to
brachytherapy; accrual to the trial is vitally important.
In conclusion, the morbidity observed in this
multiinstitutional, cooperative group study was
slightly higher than that reported in recent RTOG stu-
dies using brachytherapy alone or high-dose external-
beam radiotherapy. The BR rate observed in this
report was similar to that observed with high-dose
external-beam radiotherapy alone in similar patients.
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